Novartis
FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis
December 6, 2019Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma
The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …
Amazon and Novartis team up on cloud services
December 5, 2019Sales and Marketing Amazon Web Services, Cloud services, Novartis, amazon, pharma, product lines
Novartis is teaming up with Amazon Web Services to utilise its cloud computing technology. The collaboration is designed to overhaul …
Drugmakers cut prices by 61% to get on Chinese reimbursement list
November 28, 2019Manufacturing and Production AstraZeneca, China, China National Reimbursement Scheme, Novartis, Roche Holding
AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s …
Novartis acquires The Medicines Company in a deal worth $9.7 billion
November 25, 2019Sales and Marketing Novartis, The Medicines Company, pharma
Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
November 18, 2019Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease
November 18, 2019Sales and Marketing Adakve, Novartis, pharma, sickle cell disease
The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …
Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma
NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …
Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis
November 11, 2019Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma
The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis
November 1, 2019Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma
Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
October 31, 2019Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
FDA slams brakes on trial for world’s most expensive drug following safety concerns in children
October 30, 2019Research and Development FDA, Novartis, Zolgensma, pharma
The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million …
Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows
October 10, 2019Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis
Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
Novartis’ ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance
October 9, 2019Research and Development Novartis, legelizumab, pharma, urticaria
Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …
FDA approves Novartis’ Beovu injection for wet age-related macular degeneration
October 8, 2019Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma
Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
